Zymeworks Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
ZYME$31.46+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Expressed in thousands of U.S. dollars)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(39,921) | $(99,189) |
| Items not involving cash: | ||
| Depreciation of property and equipment | 2,771 | 3,191 |
| Amortization of intangible assets | 3,871 | 2,494 |
| Stock-based compensation expense | 19,184 | 12,771 |
| Amortization of operating lease right-of-use assets | 2,461 | 1,819 |
| Impairment of acquired IPR&D (note 6) | — | 17,287 |
| Deferred income tax recovery | (465) | (436) |
| Change in fair value of contingent consideration liability | — | (1,878) |
| Unrealized foreign exchange loss (gain) | 227 | (588) |
| Changes in non-cash operating working capital: | ||
| Accounts receivable | 26,487 | (4,729) |
| Prepaid expenses and other current assets | 11,629 | (4,159) |
| Accounts payable and accrued liabilities | (24,983) | 6,985 |
| Operating lease liabilities | (2,504) | (7,531) |
| Deferred revenue | (22,391) | 5,154 |
| Income taxes payable | 888 | 261 |
| Net cash provided used in operating activities | (22,746) | (68,548) |
| Cash flows from financing activities: | ||
| Issuance of common stock on exercise of stock options | 10,079 | 8,072 |
| Issuance of common stock through employee stock purchase plan | 1,425 | 930 |
| Purchases of common stock for retirement (note 8b) | (16,216) | (20,624) |
| Private placement for issuance of common stock (note 8c) | 4,988 | — |
| Deferred financing costs | (93) | (174) |
| Net cash provided by (used in) financing activities | 183 | (11,796) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (139,233) | (229,923) |
| Proceeds from marketable securities | 162,160 | 277,645 |
| Acquisition of property and equipment | (940) | (1,677) |
| Acquisition of intangible assets | (692) | (1,075) |
| Net cash provided by investing activities | 21,295 | 44,970 |
| Effect of exchange rate changes on cash and cash equivalents | (1) | 173 |
| Net change in cash and cash equivalents | (1,269) | (35,201) |
| Cash and cash equivalents, beginning of period | 66,103 | 157,557 |
| Cash and cash equivalents, end of period | $64,834 | $122,356 |
| Supplemental cash flow information: | ||
| Net cash paid during the period for income taxes | $1,243 | $212 |
| Supplemental disclosure of non-cash investing and financing items: | ||
| Issuance of common stock upon exercise of pre-funded warrants (note 8c) | $49,862 | $— |
| Leased assets obtained in exchange for operating lease liabilities | 2,443 | 644 |
| Purchases of common stock not settled | 504 | 500 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.